PEG-MGF: The Complete Guide

PEG-MGF is a research-chemical construct: the synthetic 24-amino-acid C-terminal E-peptide of human IGF-1Ec (the alternative-splice product of the IGF-I gene), conjugated to a polyethylene glycol (PEG) moiety.

This molecule is not endogenous and has never appeared in any human or animal tissue. Pegylation is a synthetic post-translational modification. “PEG-MGF” exists only because someone made it.

Three identity layers must be kept distinct:

1. Endogenous IGF-1Ec mRNA / pre-pro-IGF-1Ec protein. Alternative splice variant of the IGF1 gene transcribed by mechanically loaded skeletal muscle. Cloned from rabbit muscle by the Goldspink group (Yang 1996, PMID 8884603). Translated as a 113-aa pre-pro-IGF-1Ec, post-translationally cleaved into mature native IGF-1 plus the unique E-peptide tail.
2. The cleaved 24-aa E-peptide. Hypothesized by the Goldspink group to act on satellite cells via a non-IGF-1R receptor. The proposed “MGF receptor” has never been cloned, named, or characterized in any peer-reviewed paper — it is an inferred entity, not a defined molecular target.
3. Synthetic PEG-MGF (the research chemical). The 24-aa E-peptide solid-phase-synthesized, then conjugated to PEG. In legitimate research-supply (Bachem, Tocris), the PEG molecular weight, attachment chemistry, and stoichiometry are documented per-batch. In black-market PEG-MGF, none of these parameters is reliably known (Esposito 2012, PMID 22328223 — mass-spec characterization of black-market analogs with undisclosed D-Arg, His-substitution, amidation, variable PEG attachment).

Regulatory status:

• FDA (US): not approved. No IND, no NDA / BLA, no orphan designation. Has never advanced into formal pharmaceutical development. Mecasermin (Increlex) is recombinant native IGF-I, NOT IGF-1Ec, NOT the E-peptide, NOT pegylated. Increlex’s existence does not give regulatory cover to PEG-MGF.
• PEGylated IGF-1 IS in active pharma development (Kletzl 2017, PMID 28110155; Braun 2018, PMID 29634992). PEG-IGF-1 is not PEG-MGF. The pharma industry has actively pursued PEG-IGF-1 but has not pursued PEG-MGF, even though the underlying MGF concept has been around since 1996. The lack of pharma uptake is itself a signal.
• EMA: no marketing authorization.
• WADA 2026: prohibited at all times under S2.3 — the Prohibited List names “mechano growth factors (MGFs)” as a separately enumerated entry. PEG conjugation does not exempt it.

PEG-MGF inherits all the mechanistic claims of the underlying 24-aa MGF E-peptide. There is no additional PEG-MGF-specific mechanism. The PEG is held to be pharmacologically inert — it only extends the kinetic window.

Goldspink-group narrative (canonical, contested):

1. Mechanical loading / muscle damage → IGF-1 pre-mRNA splices toward the Ec (MGF) isoform for ~24 hr (Hill 2003, PMID 12692175 — rodent damage timecourse; Hameed 2003, PMID 12562960 — human exercise upregulation in young but not old men).
2. Pre-pro-IGF-1Ec is cleaved → mature IGF-1 plus the 24-aa Ec E-peptide.
3. The E-peptide is hypothesized to act independently of IGF-1R — Dłużniewska 2005 (PMID 16144956) reported neuroprotection that persisted under IGF-1R blockade, motivating a distinct (uncloned, unnamed) receptor.
4. The E-peptide activates quiescent satellite cells, driving proliferation and delaying terminal differentiation (Mills 2007 PMIDs 17156777, 17845560; Ates 2007 PMID 17531227; Kandalla 2011 PMID 21354439).
5. Subsequently splicing reverts toward Ea, supporting differentiation / fusion.

The reproducibility challenge (load-bearing):

PMID 24253050 (Fornaro et al., Am J Physiol Endocrinol Metab 2014). Joint Novartis + GSK study. Same MGF-Ct24E peptide as the Goldspink-group studies. Tested on C2C12, primary human myoblasts, primary mouse muscle stem cells, up to 500 ng/mL. No proliferative or anti-differentiation effect. Full-length IGF-I positive control worked as expected. Accompanying editorial: PMID 24460193 (Rotwein, Mol Endocrinol 2014, “The fall of mechanogrowth factor?”).

The Fornaro paper has not been refuted by an equally rigorous follow-up. Honest position: the proliferative E-peptide effect is contested. PEG-MGF is the proposed long-acting clinical version of a molecule whose underlying bioactivity has not been independently reproduced at industrial-lab rigor.

What pegylation adds (in theory):

Per Veronese & Mero 2008 (PMID 18778113, the canonical PEG-biologics review):

• Increased hydrodynamic radius → reduced renal filtration → longer plasma half-life.
• Shielding from proteolytic degradation → longer in-vivo persistence.
• Reduced immunogenicity vs unmodified peptide — weaker for endogenous-sequence peptides like the human MGF E-peptide.
• Potential for accelerated clearance after repeated dosing if anti-PEG antibodies develop.

None of these effects has been measured for PEG-MGF specifically.

The two names sit on top of three actually-different molecules. Don’t conflate them.

Name	Molecule	Half-life claim	Anchored?
Endogenous MGF / IGF-1Ec mRNA	Spliced IGF-1 mRNA + cleaved E-peptide in muscle	mRNA pulse ~1 day post-injury (PMID 12692175)	Yes, T2 (mRNA only)
Synthetic non-PEG MGF	24-aa E-peptide, solid-phase synthesized	Vendor-cited “5–7 minutes”	No — T4 only
Synthetic PEG-MGF	Same 24-aa E-peptide, conjugated to PEG (typically 5/10/20/40 kDa)	Vendor-cited “48–72 hours”	No — T4 only; T2 class rationale via PMID 18778113

Audit-critical points:

1. The Goldspink-group preclinical positive findings all used non-PEG synthetic 24-aa E-peptide. No published preclinical study has compared PEG-MGF to non-PEG MGF head-to-head.
2. The Fornaro 2014 reproducibility failure was on non-PEG synthetic 24-aa E-peptide. PEG-MGF would, by the Goldspink logic that PEG is inert, behave the same as non-PEG MGF for longer — meaning PEG-MGF inherits the reproducibility problem without independent positive evidence.
3. PEG-MGF is NOT PEG-IGF-1. PEG-IGF-1 (Kletzl 2017, Braun 2018) is full-length recombinant 70-aa human IGF-I PEGylated. PEG-MGF is the 24-aa C-terminal E-peptide PEGylated. Their proposed pharmacologies are mechanistically distinct (IGF-1R agonism vs hypothesized non-IGF-1R “MGF receptor”). Conflating them would be a serious error.
4. PEG-MGF is NOT IGF-1 LR3. LR3 is full-length IGF-1 with N-terminal extension and Arg³ substitution — not pegylated, not the E-peptide. Some bodybuilding-community summaries blur PEG-MGF and LR3 as “long-acting IGF family” — they aren’t interchangeable. See the IGF-1 LR3 guide.

No published trial of PEG-MGF for any indication. No PK study, no safety study, no efficacy study. The dosing below is vendor / community convention.

Parameter	Common Range
Dose per injection	200–400 µg
Frequency	1–2× per week (the long-half-life rationale of PEG vs daily for non-PEG)
Timing	Post-workout (community convention)
Cycle length	4–8 weeks on / similar off
Route	SC (community standard); the longer half-life makes the post-workout ultra-local IM rationale of non-PEG MGF largely irrelevant

Note that the 200–400 µg range and twice-weekly cadence both come from vendor / community sources, not from a Phase 1 dose-finding study. The numbers are not anchored.

Standard SC peptide reconstitution. For a typical 2 mg lyophilized vial:

• Add 2 mL bacteriostatic water → 1 mg/mL (1000 µg/mL).
• On a U-100 insulin syringe, 1 unit = 10 µg.
• So a 200 µg dose = 20 units; a 400 µg dose = 40 units.

Storage:

• Lyophilized: stable at room temperature short-term; refrigerate for longer.
• Reconstituted: refrigerate. Use within 28 days.
• The PEG conjugation generally improves stability vs unmodified peptide (Veronese 2008), but PEG-MGF-specific stability data is not published.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

No published safety data on PEG-MGF. No FAERS, EudraVigilance, or Yellow Card entries because the molecule has never been approved.

Theoretical / class concerns:

• Anti-PEG antibodies. Documented for the PEG-biologics class (Veronese 2008, PMID 18778113). Chronic PEG-MGF dosing could induce anti-PEG IgM/IgG → accelerated clearance ("ABC phenomenon") and potential allergic-style reactions on subsequent doses. Not characterized for PEG-MGF.
• Cancer-axis concern. The hypothesized non-IGF-1R “MGF receptor” is uncharacterized; its tumorigenic potential is unknown. The IGF-1Ec splice variant has been associated with multiple cancer types in expression studies (cancer cells re-express MGF transcripts). Active or prior cancer is a class contraindication.
• Local injection-site reactions — common to all SC peptides.
• Localized tissue overgrowth at the injection site — theoretical with chronic SC dosing into the same area.
• Edema / sodium retention — if any IGF-axis spillover occurs (the hypothesized non-IGF-1R mechanism would not predict this, but the molecule has not been characterized in vivo to rule it out).

Community user reports describe mild injection-site irritation as the most common acute issue. None of this is anchored in a peer-reviewed safety paper.

• Pregnancy / breastfeeding — no safety data.
• Active or prior cancer — class concern. The MGF / IGF-1Ec gene is upregulated in multiple cancer cell lines; mechanism extrapolation is bidirectional and the conservative position is no use.
• Known anti-PEG antibody history — relevant for any patient who has been treated with PEGylated biologics (PEG-asparaginase, PEG-rhGH, etc.).
• Concurrent use of other IGF-axis modulators (HGH, IGF-1 LR3, IGF-1 DES, MGF) — uncharacterized stacking; theoretical additive risk.
• Athletes subject to anti-doping testing — do not use. WADA S2.3 names “mechano growth factors (MGFs)” explicitly; PEG conjugation does not exempt.

This section exists because PEG-MGF’s evidence base is unusually thin even by gray-market peptide standards. Three things to know before committing time or money:

1. Zero PubMed-indexed primary studies on PEG-MGF.

Verified 2026-05-07: PubMed search for “PEG-MGF” returns 0 hits. Search for “pegylated mechano growth factor” returns 4 hits, all about PEG-IGF-1 or PEG-rhGH (different molecules entirely). The 48–72 hour half-life claim, the satellite-cell mechanism claim, the dosing convention — none of it is anchored to PEG-MGF-specific peer-reviewed data.

2. The underlying non-PEG MGF E-peptide bioactivity is contested.

Goldspink-group positive findings (Mills 2007 PMIDs 17156777, 17845560; Ates 2007 PMID 17531227; Kandalla 2011 PMID 21354439; Carpenter 2008 PMID 17581790) all predate the Fornaro 2014 reproducibility failure (PMID 24253050) by Novartis + GSK. The Fornaro paper has not been refuted by an equally rigorous follow-up.

3. The pharma industry pursued PEG-IGF-1 but did not pursue PEG-MGF.

Roche / Genentech / others took PEG-IGF-1 into Phase 1 (Kletzl 2017, PMID 28110155). No equivalent program exists for PEG-MGF, even though the underlying MGF concept has been around since 1996. The lack of pharma uptake is a real signal about how the proposition looks to internal scientific review.

If you decide to use PEG-MGF anyway, do so with eyes open about what the literature actually supports and what it doesn’t.

• MGF (non-PEG) — same 24-aa E-peptide, no PEG. Vendor-claimed 5–7 min half-life vs PEG-MGF’s claimed 48–72 hr. Both half-life figures are unanchored.
• IGF-1 LR3 — full-length 70-aa IGF-I with N-terminal extension and Arg³ substitution. NOT PEGylated. NOT the E-peptide. Different mechanism.
• IGF-1 DES — full-length 67-aa IGF-I missing N-terminal Gly-Pro-Glu. NOT PEGylated. NOT the E-peptide. Different mechanism.
• PEG-IGF-1 (Roche / Genentech pharma program) — full-length recombinant human IGF-I PEGylated. NOT PEG-MGF. Real pharmaceutical development category; not what you buy as “PEG-MGF” from a research-chemical vendor.
• Mecasermin (Increlex) — FDA-approved recombinant native IGF-I for severe primary IGF-I deficiency. NOT MGF. NOT pegylated. Increlex’s existence does not give regulatory cover to PEG-MGF.
• HGH / Somatropin — recombinant human growth hormone, full 191-aa protein. Different molecule entirely; different receptor; different regulation.